A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

Additionally, investors may have begun repositioning portfolios ahead of the release of second-quarter earnings results.

CRISPR Therapeutics AG CRSP shares rallied 9.6% in the last trading session to close at $60.08. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Names including Kohls, Plug Power, and Mara Holdings round out the list of the market's top 10 most-shorted stocks.

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. | KJ ...

In this interview, Professor James J. Collins, founder of the field of Synthetic Biology, discusses his journey to founding ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.26%. Read on to learn why. Crispr Therapeutics AG has seen a notable ...

CRISPR Therapeutics could stage a comeback thanks to clinical and commercial progress. There are many promising corporations ...